Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.
Sound Bioventures Fund I AB is a registered alternative investment fund, under the Swedish Alternative Investment Funds Managers Act. The target size for the fund is EUR 150 million.
Investment strategy and approach
Our investment and portfolio construction strategy builds on lessons learned and approach perfected during the 12 years the founding team worked together making over 30 investments, many of which were in clinical stage rare/orphan disease companies. We can lead, co-lead or follow.
Therapeutic area focus
Specialty therapeutic areas and diseases with significant clinical unmet need. All modalities and therapeutic approaches are in scope. Medical devices and digital health approaches are out of scope. Also out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story.
Additionally, we want to make a difference for the company i.e. we invest in companies, where it is possible for a private investor or venture syndicate to finance the R&D program all the way to an NDA, should this become necessary.
Stage of company
We invest in about-to-be clinical or clinical stage companies where the investment will result in a clinical readout in the lead asset. Platform companies are also attractive, as long as the lead asset will get a clinical readout with the financing.
Geographic footprint
Scandinavia, rest of Europe, and USA. We believe companies need to be built with a global perspective in mind and in this virtual world, having people on different countries or even continents is becoming the norm.
Please submit investment proposals to info@soundbioventures.com